Document is current
Any future updates will be listed below
-
Authors
Murer, Patrizia https://orcid.org/0009-0002-2240-915X
Petersen, Laetitia
Egli, Nicole
Salazar, Ulisse https://orcid.org/0009-0008-8041-3222
Neubert, Pia
Zurbach, Anaïs
Rau, Alexander https://orcid.org/0000-0001-6810-2714
Stocker, Christian
Reichenstein, Dario
Katopodis, Andreas
Huber, Christoph
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06470763 at ClinicalTrials.govDocuments that mention this clinical trial
954 ANV600, a <i>cis</i>-signaling αPD-1/IL-2Rβ/γ agonist, expands both CD4+ and CD8+ tumor-specific T cells by acting in the tumor microenvironment and draining lymph nodes
https://doi.org/10.1136/jitc-2024-sitc2024.0954
ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy
https://doi.org/10.1136/jitc-2025-011905
-
Funding
Funding for this research was provided by:
ANAVEON AG (N/A)
- License Information
